Immunic Q2 2023 Earnings Report
Key Takeaways
Immunic reported important clinical and preclinical data from its two lead pipeline programs, including vidofludimus calcium (IMU-838) and IMU-856. The company announced preclinical evidence showing vidofludimus calcium acts as a potent Nurr1 activator and reported positive results from the part C portion of its phase 1 clinical trial of IMU-856 in patients with celiac disease.
Published preclinical data in the Journal of Medicinal Chemistry identifies Vidofludimus Calcium as a potent Nurr1 activator, reinforcing neuroprotective potential in multiple sclerosis.
Reported positive results from Phase 1b clinical trial of IMU-856 in Celiac Disease, providing proof-of-concept for a new therapeutic approach to treat gastrointestinal diseases.
Expects interim results from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis in the Fall of 2023.
Cash, cash equivalents and investments of $77.3 million is expected to fund Immunic into the fourth quarter of 2024.